DRUG DEVELOPMENT DIRECT

WEEKLY NEWSLETTER

December 19, 2018

  Highlight: Parenteral Contract Manufacturing

  MARKET NEWS

Histo-Scientific Research Laboratories & Vet Path Services Merge
Kiniksa Announces Rilonacept Interim Phase 2 Clinical Data; Initiates Pivotal Phase 3 Clinical Trial
SunGen Pharma Receives Its Second & Third ANDA Approval from US FDA
Intensity Therapeutics Strengthens Intellectual Property Portfolio With Issuance of Several New Patents
Aravive Biologics Initiates Phase 1b Portion of Phase 1b/2 Clinical Trial
Entera Bio & Amgen Enter Strategic Research Collaboration

  FEATURED EDITORIAL

  COMPANY PROFILE

Vetter is a leading contract development and manufacturing organization (CDMO) that specializes in the aseptic filling of syringes, cartridges, and vials. Vetter holds numerous patents and has extensive experience with biologics and other complex compounds, including monoclonal antibodies, peptides, interferons, and vaccines. More than 80% of Vetter’s active projects are biologics, and Vetter currently manufactures 5 of the world’s top 10. Collaborating with the top 20 (bio-)pharmaceutical companies worldwide, Vetter supports products from preclinical development through global market supply. Through its US and European facilities, Vetter Development Service provides state-of-the-art support for early stage products, with seamless transfer at Phase III to Vetter Commercial Manufacturing for large-scale production. We offer state-of-the-art technology and innovative processes to promote product quality and maximize API yield. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Croda Acquires Biosector; Strengthens Pharmaceutical Offering

Croda Acquires Biosector; Strengthens Pharmaceutical Offering

Croda International Plc, the speciality chemical company that creates high performance ingredients and technologies relied upon by industry and consumers globally, recently announced that it has strengthened its pharmaceutical offering by signing a definitive agreement with Brenntag Nordic A/S to acquire Brenntag Biosector (Biosector).

Y-mAbs Therapeutics Announces FDA Clearance of IND

Y-mAbs Therapeutics Announces FDA Clearance of IND

Y-mAbs Therapeutics, Inc. recently announced the US FDA has cleared the Investigational New Drug (IND) application for a humanized bispecific GD2 antibody.

Quotient Sciences & Druggability Technologies Announce Collaboration

Quotient Sciences & Druggability Technologies Announce Collaboration

Quotient Sciences and Druggability Technologies recently announced a collaboration to utilize Quotient’s integrated Translational Pharmaceutics platform to advance the development of DRGT-46, a novel, fast-acting formulation of celecoxib using proprietary super-API compositions developed by DRGT.

Cambrex Expands Analytical Capabilities

Cambrex Expands Analytical Capabilities

Cambrex Corporation recently announced it is investing $1 million at its High Point, NC, site to fit out 1,300 sq ft of analytical laboratory space and plans to hire 9 chemical research and development scientists, as well as 6 analytical research and development scientists pursuant to this project.

Cartridge Filling: Combination of Features That Can Help Gain a Competitive Edge

Cartridge Filling: Combination of Features That Can Help Gain a Competitive Edge

By 2050, it is projected that the proportion of people aged 65 and older will be more than double that of children aged 5. This global phenomenon is also leading to an increasing number of people suffering from chronic diseases, such as diabetes and osteoporosis.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

January 9 – Capsules
January 16 – Excipients